Evaluation of efficacy and safety of two antihyperlipidemics as an adjunctive therapy in patients of mixed dyslipidemia, who are already on treatment with statins: an open-label, comparative, multicentric study.

Fax: 631-656-10060 个研究点目标入组 200 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male or Female patients aged between 18 to 70 years.
•2.Patients with Fasting TG &≥ 150mg/dl, HDL-C < 40mg/dl for men and < 50mg/dl for women and LDL-C & ≥130mg/dl.
•3.Patients who are already on statin for at least 4 weeks and not adequately controlled.
•4.Patients willing to give their informed consent.

•1.Pregnant, lactating women or women of childbearing age who are not using an acceptable method of birth control.
•2.Patients with cardiovascular disease, type 1 diabetes mellitus.
•3.Patients with significantly abnormal laboratory analysis of thyroid function.
•4.Patients with severe renal impairment, including those receiving dialysis.
•5.Patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities.
•6.Patients with preexisting gallbladder disease.
•7.Patients with hypersensitivity to fenofibric acid or statin.
•8.Patients taking oral coumarin anticoagulant.
•9.Patient on treatment cyclosporine, niacin (nicotinic acid), erythromycin, azole antifungals.
•10.Patients taking antacid, Colestipol.
•11.Patients on treatment of endogenous steroid hormones such as ketoconazole, spironolactone, and cimetidine

发起方

Fax: 631-656-1006